Released : September 19, 2017 07:00 RNS Number : 0903R MaxCyte, Inc. 19 September 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2017 Maryland, USA - 19 September 2017 - MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the
Gaithersburg, Maryland – September 14, 2017 : MaxCyte, a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that Madhusudan V. Peshwa, PhD, MaxCyte Chief Scientific Officer,
Released : August 25, 2017 07:00 RNS Number : 9391O MaxCyte, Inc. 25 August 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Maryland, USA - 25 August 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
25-year biopharma industry veteran joins the Company to drive further growth of its innovative high-performance cell engineering platform for use in commercial drug development Gaithersburg, Maryland – August 14, 2017: MaxCyte, a US-based global company dedicated to driving the acceleration of the
Released : July 20, 2017 18:02 RNS Number : 6906L MaxCyte, Inc. 20 July 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery,
Released : July 12, 2017 07:00 RNS Number : 7813K MaxCyte, Inc. 12 July 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Maryland, USA - 12 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development,
Released : June 06, 2017 07:00 RNS Number : 2054H MaxCyte, Inc. 06 June 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Cooperative Research and Development Agreement MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease
Released : May 31, 2017 16:30 RNS Number : 7231G MaxCyte, Inc. 31 May 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA -31 May 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 22,435 new shares of common stock of $0.01
Released : May 02, 2017 13:42 RNS Number : 9212D MaxCyte, Inc. 02 May 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Block Listing Application MaxCyte (AIM: MXCT, MXCR) provides notification that an application has been made to the London Stock Exchange for admission to AIM for a block
Released : April 25, 2017 18:27 RNS Number : 3255D MaxCyte, Inc. 25 April 2017 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which
